Barr’s Bijuva Estrogen Cream Is “Not Approvable” At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will require additional clinical evidence pertaining to an unmet endpoint, Barr says. Two of three endpoints for the synthetic conjugated estrogens cream were met during clinical studies; the third was modified at FDA’s guidance after the trials began, the company says.